This week in BMJ

All communications to: The Editor, BMJ BMA House, Tavistock Square London WC1H 9JR Fax: 071 383 6418 Phone: 071 387 4499

Editor Richard Smith

ABCs editor Deborah Reece

Design editor Derek Virtue

Editorials Tony Delamothe

Editorial secretaries Gaby Shockley Margaret Benfell Kathryn Sims

General office Leslie Moore Andrew Woodward John Mayor Gary Bryan

Letters Alison Tonks

News and Medicopolitical digest Linda Beecham Luisa Dillner Trish Groves Jane Smith

Obituaries Liz Crossan

Papers Fiona Godlee

Papers secretaries Susan Minns Marita Batten

Registrar Stuart Handysides

Reviews Ruth Holland

Technical editors
Jacqueline Annis
Tony Camps-Linney
Margaret Cooter
Greg Cotton
Sharon Davies

Associate editors Tessa Richards Roger Robinson Tony Smith

Editorial advisers Teifion Davies Ian Forgacs John Garrow Trish Greenhalgh Iona Heath Richard Hobbs Duncan Keeley David Jewell Mike Pringle John Rees John Seadding

Statistical advisers
Doug Altman
Mike Campbell
Tim Cole
Stephen Evans
David Machin
Ken Macrae
Julie Morris

Executive director Geoffrey Burn

Books division manager Neil Poppmacher

Director of business development Bob Hayzen

Group product manager Eunice Walford

Sales director journals Maurice Long

Production director Derek Parrott

Advertisement sales Sue Bound Euan Currer Richard Purdy

Choice of drugs in early parkinsonism is not critical

Levodopa in combination with a dopa decarboxylase inhibitor is the most effective treatment for Parkinson's disease, but because of levodopa's adverse effects in the long term neurologists are divided on which is the best treatment for the early stages of the disease. On p 469 the Parkinson's Disease Research Group of the United Kingdom report the interim results of its long term prospective randomised trial of three treatments in 782 untreated patients with early Parkinson's disease. The three treatments are levodopa and benserazide (arm 1); levodopa, benserazide, and selegiline (arm 2); and bromocriptine (arm 3). After three years of the trial all treatments were effective in reducing disability; arms 1 and 2 were not significantly different but both were significantly better than arm 3 and had fewer early adverse reactions. However, the incidence of dyskinesias and motor oscillations was significantly lower in arm 3. The choice of treatment may therefore not be critical in early parkinsonism, although later results may detect significant differences.

Community psychiatric services help relatives as well as patients

Several studies have evaluated the effectiveness of community treatment for acute episodes of psychiatric illness compared with traditional hospital based services but none has assessed in detail the effect on relatives and friends. On p 473 Dean et al compared a hospital and community service and found that relatives and friends were less distressed and more satisfied with the service in the community treated group. More of the community treated group were still in contact with doctors and nurses a year later. Although a quarter of the community group still required admission to hospital, overall the use of beds was 80% less in that group.

Spinal cord stimulation in angina pectoris induced by pacing

Spinal cord stimulation has been used in recent years to treat angina pectoris that is intractable despite optimal medical and surgical treatment. The clinical results are promising and offer a new therapeutic possibility to a group of patients for whom conventional management strategies are insufficient. The antianginal effect of spinal cord stimulation is, according to recent reports, associated with a reduction in myocardial ischaemia. Mannheimer et al (p 477) studied the effects of spinal cord stimulation in angina pectoris induced by atrial pacing. Twenty patients were investigated in a control session and during spinal cord stimulation. During stimulation, at a pacing rate comparable to that producing angina during the control recording, anginal pain was absent or less intense, myocardial lactate metabolism was improved, and myocardial oxygen consumption decreased. These results show that spinal cord stimulation has an anti-ischaemic effect in coronary artery disease.

Prescription weightings underestimate prescribing costs for middle aged patients

Closer monitoring of general practitioners' prescribing patterns has highlighted the difficulties of comparing prescribing rates for populations of different demographic composition. In an attempt to calculate more sensitive weightings than the current weighting of 3 for patients aged 65 and over Roberts and Harris analysed data from 90 practices (p 485). Their new weightings, based on age, sex, and temporary resident status and on the cost of items prescribed rather than the number, more accurately accounted for variation in prescribing due to patients' age and sex. In particular prescribing costs increased in patients aged 35-64. At practice level the new weightings make a difference—but even so account for only 25% of the variation in prescribing costs between practices.

British and French psychiatrists do not share the same concept of schizophrenia

Reflecting a growing interest in differences in medical practice within Europe, Van Os et al show that the incidence of schizophrenia, as recorded in national statistics, varies greatly between the United Kingdom and France (p 489). Rates of first admission for schizophrenia are higher in France than in Britain for people aged under 45 but lower after that age; rates are falling in Britain but rising in France. The authors followed up this finding with a questionnaire study of 92 psychiatrists in the United Kingdom and 69 in France to assess their concept of schizophrenia. British and French psychiatrists showed substantial differences over 31 out of 38 statements about the cause, diagnosis, management, and outcome of schizophrenia. In particular, French psychiatrists did not diagnose the condition after the age of 45 and endorsed more psychoanalytical concepts than their British counterparts.

Measures to take in women of childbearing age with epilepsy

The risk of fetal abnormalities is increased in women taking antiepileptic drugs, and a child inherits epileptic liability from both parents. Epileptic women of childbearing age thus have a series of questions they need to ask about pregnancy; on p 492 O'Brien and Gilmour-White try to answer the common ones. The small increased risk of fetal abnormalities is increased further if the mothers are taking antiepileptic drugs; this risk rises with the number of drugs being taken, so women contemplating pregnancy should be given a single drug at the lowest possible dose. All women taking antiepileptic drugs should have their babies delivered in hospital to ensure adequate antiepileptic treatment, though the risk of status epilepticus is low. The authors point out that maternal epilepsy probably presents a greater risk to infants (through uncontrolled epilepsy) than to the fetus.